Venture NAV Tracker / Private company
Heron Therapeutics, Inc.
Headquarters—
Founded—
Last known round—
Reported valuation—
+1020.6% equity-mark dispersion. Hercules Capital, Inc. carries Heron Therapeutics, Inc. at $0.07/share; Hercules Capital, Inc. carries it at $0.80/share. Review dates and security types before treating those marks as directly comparable.
Cross-fund comparison
Equity & warrant marks
One latest disclosed mark per fund.
| Fund | Fair value | Security / basis | Implied price / share | Mark age vs round | Methodology / filing |
|---|---|---|---|---|---|
| HTGCHercules Capital, Inc. | $292KMar 31, 2026 · source ↗ | equityFair Value | $0.80Not comparable — different security type or share classMar 31, 2026 · source ↗ | —Mar 31, 2026 · source ↗ | 10-Q 2026-03-31 ↗ |
| HTGCHercules Capital, Inc. | $17KMar 31, 2026 · source ↗ | warrantFair Value | $0.07Not comparable — different security type or share classMar 31, 2026 · source ↗ | —Mar 31, 2026 · source ↗ | 10-Q 2026-03-31 ↗ |
Cross-fund comparison
Debt investments
One latest disclosed debt mark per fund.
| Fund | Security type / basis | Principal | Fair value | FV / principal | Rate | Maturity | Mark age vs round | Non-accrual |
|---|---|---|---|---|---|---|---|---|
| HTGCHercules Capital, Inc. | senior secured loanFair Value — Senior Secured | $80.6MMar 31, 2026 · source ↗ | $79.2MMar 31, 2026 · source ↗ | 98.3%Mar 31, 2026 · source ↗ | Prime + 1.95 %, Floor rate 9.45 %, PIK Interest 1.00 %, 6.50 % Exit FeeMar 31, 2026 · source ↗ | Sep 1, 2030Mar 31, 2026 · source ↗ | —Mar 31, 2026 · source ↗ | NoMar 31, 2026 · source ↗ |
Historical marks
Reported fair value by fund
Each bar is a disclosed position-quarter.